Erratum: Immune activation alters cellular and humoral responses to yellow fever 17D vaccine (Journal of Clinical Investigation (2014) 124:7 (3147-3158) DOI: 10.1172/JCI75429);Immune activation alters cellular and humoral responses to yellow fever 17D vaccine

Journal of Clinical Investigation

Volumn 124, Issue 7, 2014, Pages 3147-3158

  Muyanja, Enoch ^a   Ssemaganda, Aloysius ^a   Ngauv, Pearline ^b   Cubas, Rafael ^b   Perrin, Helene ^b   Srinivasan, Divya ^b   Canderan, Glenda ^b   Lawson, Benton ^c   Kopycinski, Jakub ^d   Graham, Amanda S ^e   Rowe, Dawne K ^e   Smith, Michaela J ^e   Isern, Sharon ^e   Michael, Scott ^e   Silvestri, Guido ^c   Vanderford, Thomas H ^c   Castro, Erika ^f   Pantaleo, Giuseppe ^f,g   Singer, Joel ^h   Gillmour, Jill ^d   Kiwanuka, Noah ^a,i   Nanvubya, Annet ^a   Schmidt, Claudia ⁱ   Birungi, Josephine ^a   Cox, Josephine ^d   Haddad, Elias K ^b   Kaleebu, Pontiano ^a,j   Fast, Patricia ^d   Sekaly, Rafick Pierre ^b   Trautmann, Lydie ^b   more..

^a UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^b Vaccine and Gene Therapy Institute of Florida   (United States)

^c EMORY UNIVERSITY   (United States)

^d INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^e FLORIDA GULF COAST UNIVERSITY   (United States)

^f Division of Immunology and Allergy   (Switzerland)

^g LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^h CANADIAN INSTITUTES OF HEALTH RESEARCH   (Canada)

ⁱ MAKERERE UNIVERSITY SCHOOL OF PUBLIC HEALTH   (Uganda)

^j MEDICAL RESEARCH COUNCIL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; HLA ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; YELLOW FEVER VACCINE; YELLOW FEVER VACCINE 17D;

ADAPTIVE IMMUNITY; ADULT; AFRICA; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COHORT ANALYSIS; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOLOGICAL PARAMETERS; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MEMORY CELL; MEMORY T LYMPHOCYTE; MONOCYTE; NATURAL KILLER CELL; PRIORITY JOURNAL; SWITZERLAND; T LYMPHOCYTE ACTIVATION; UGANDA; UNSPECIFIED SIDE EFFECT; VACCINATION; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

ADAPTIVE IMMUNITY; ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; B-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNITY, INNATE; IMMUNIZATION, SECONDARY; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MONOCYTES; SWITZERLAND; UGANDA; VACCINES, ATTENUATED; VIRUS REPLICATION; YELLOW FEVER; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS; YOUNG ADULT;

EID: 84903755816     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI77956     Document Type: Erratum

References (55)

1. Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ. 1981;59(6):895-900.
2. Monath TP, Barrett AD. Pathogenesis and pathophysiology of yellow fever. Adv Virus Res. 2003;60:343-395.
3. Niedrig M, Lademann M, Emmerich P, Lafrenz M. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop Med Int Health. 1999;4(12):867-871.
4. Monath TP, Cetron MS, Teuwen DE. Yellow fever vaccine. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 5th ed. Philadelphia, Pennsylvania, USA: Saunders Elsevier; 2008:959-1055.
5. Staples JE, Gershman M, Fischer M. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59(RR-7):1-32.
6. Gotuzzo E, Yactayo S, Cordova E. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg. 2013;89(3):434-444.
7. World Health Organization. Yellow fever fact sheet No100. WHO Web site. http://www.who.int/ mediacentre/factsheets/fs100/en/. Updated March 2014. Accessed May 13, 2014.
8. Querec TD, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol. 2008;10(1):116-125.
9. Gaucher D, et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med. 2008;205(13):3119-3131.
10. Reinhardt B, Jaspert R, Niedrig M, Kostner C, L?age-Stehr J. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol. 1998;56(2):159-167.
11. Silva ML, et al. Characterization of main cytokine sources from the innate and adaptive immune responses following primary 17DD yellow fever vaccination in adults. Vaccine. 2011;29(3):583-592.
12. Barba-Spaeth G. Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes. J Exp Med. 2005;202(9):1179-1184.
13. Martins MA, et al. Activation/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: is this the key to prevent severe adverse reactions following immunization? Clin Exp Immunol. 2007;148(1):90-100.
14. Mandl JN, et al. Distinctive TLR7 signaling, type I IFN production, and attenuated innate and adaptive immune responses to yellow fever virus in a primate reservoir host. J Immunol. 2011;186(11):6406-6416.
15. Co MDT, Terajima M, Cruz J, Ennis FA, Rothman AL. Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLA-B35-restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein E. Virology. 2002;293(1):151-163.
16. Santos APD, Bertho AL, Dias DC, Santos JR, Marcovistz R. Lymphocyte subset analyses in healthy adults vaccinated with yellow fever 17DD virus. Mem Inst Oswaldo Cruz. 2005;100(3):331-337.
17. Miller JD, et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity. 2008;28(5):710-722.
18. Akondy RS, et al. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol. 2009;183(12):7919-7930.
19. Rappuoli R, Aderem A. A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature. 2011;473(7348):463-469.
20. Bonaldo MC, et al. Recombinant yellow fever vaccine virus 17D expressing simian immunodeficiency virus SIVmac239 gag induces SIV-specific CD8+ T-cell responses in rhesus macaques. J Virol. 2010;84(7):3699-3706.
21. Guy B, et al. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine. 2010;28(3):632-649.
22. Martins MA, et al. Immunogenicity of seven new recombinant yellow fever viruses 17D expressing fragments of SIVmac239 Gag, Nef, and Vif in Indian rhesus macaques. PLoS One. 2013;8(1):e54434.
23. Monath TP, et al. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg. 2002;66(5):533-541.
24. Monath TP, et al. Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum Vaccin. 2005;1(5):207-214.
25. Roukens AH, et al. Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study. PLoS One. 2011;6(12):e27753.
26. Black GF, et al. BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies. Lancet. 2002;359(9315):1393-1401.
27. Lalor MK, et al. BCG vaccination induces different cytokine profiles following infant BCG vaccination in the UK and Malawi. J Infect Dis. 2011;204(7):1075-1085.
28. Gilmour J, et al. Immunogenicity of homologous and heterologous regimens of Ad26-Enva.01 and Ad35-Enva HIV vaccines in HIV-uninfected volunteers in the U.S. and Africa. AIDS Res Hum Retroviruses. 2013;29(11):A69.
29. Bhatt S, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504-507.
30. Ziegler-Heitbrock HWL. Heterogeneity of human blood monocytes: the CD14+CD16+ subpopulation. Immunol Today. 1996;17(9):424-428.
31. Moir S, et al. Normalization of B cell counts and subpopulations after antiretroviral therapy in chronic HIV disease. J Infect Dis. 2008;197(4):572-579.
32. Moir S, et al. B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. Blood. 2010;116(25):5571-5579.
33. Reynaud C-A, et al. IgM memory B cells: a mouse/human paradox. Cell Mol Life Sci. 2012; 69(10):1625-1634.
34. Yates JL, Racine R, McBride KM, Winslow GM. T cell-dependent IgM memory B cells generated during bacterial infection are required for IgG responses to antigen challenge. J Immunol. 2013;191(3):1240-1249.
35. de Melo AB, et al. T-cell memory responses elicited by yellow fever vaccine are targeted to overlapping epitopes containing multiple HLA-I and-II binding motifs. PLoS Negl Trop Dis. 2013;7(1):e1938.
36. Ovsyannikova IG, Dhiman N, Jacobson RM, Poland GA. Human leukocyte antigen polymorphisms: variable humoral immune responses to viral vaccines. Expert Rev Vaccines. 2006;5(1):33-43.
37. Yucesoy B, et al. Influence of cytokine gene variations on immunization to childhood vaccines. Vaccine. 2009;27(50):6991-6997.
38. Haralambieva IH, et al. The genetic basis for interindividual immune response variation to measles vaccine: new understanding and new vaccine approaches. Expert Rev Vaccines. 2013;12(1):57-70.
39. Yucesoy B, et al. Genetic variants within the MHC region are associated with immune responsiveness to childhood vaccinations. Vaccine. 2013; 31(46):5381-5391.
40. Lang PA, et al. Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity. Proc Natl Acad Sci U S A. 2012;109(4):1210-1215.
41. Waggoner SN, Cornberg M, Selin LK, Welsh RM. Natural killer cells act as rheostats modulating antiviral T cells. Nature. 2012;481(7381):394-398.
42. Fingerle G, et al. The novel subset of CD14+/CD16+ blood monocytes is expanded in sepsis patients. Blood. 1993;82(10):3170-3176.
43. Nockher WA, Scherberich JE. Expanded CD14+ CD16+ monocyte subpopulation in patients with acute and chronic infections undergoing hemodialysis. Infect Immun. 1998;66(6):2782-2790.
44. Zak DE, et al. Merck Ad5/HIV induces broad innate immune activation that predicts CD8+ T-cell responses but is attenuated by preexisting Ad5 immunity. Proc Natl Acad Sci U S A. 2012; 109(50):E3503-E3512.
45. Moir S, Fauci AS. B cells in HIV infection and disease. Nat Rev Immunol. 2009;9(4):235-245.
46. Anthony DD, et al. Lower peripheral blood CD14+ monocyte frequency and higher CD34+ progenitor cell frequency are associated with HBV vaccine induced response in HIV infected individuals. Vaccine. 2011;29(19):3558-3563.
47. Wisseman CL, Sweet BH. Immunological studies with group B arthropod-borne viruses. III. Response of human subjects to revaccination with 17D strain yellow fever vaccine. Am J Trop Med Hyg. 1962;11:570-575.
48. Mason RA, Tauraso NM, Spertzel RO, Ginn RK. Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl Microbiol. 1973;25(4):539-544.
49. Ben-Smith A, et al. Differences between naive and memory T cell phenotype in Malawian and UK adolescents: a role for Cytomegalovirus? BMC Infectious Diseases. 2008;8(1):139.
50. Stelekati E, Wherry EJ. Chronic Bystander Infections and Immunity to Unrelated Antigens. Cell Host and Microbe. 2012;12(4):458-469.
51. Lang J, et al. Comparison of the immunogenicity and safety of two 17D yellow fever vaccines. Am J Trop Med Hyg. 1999;60(6):1045-1050.
52. Barban V, et al. High stability of yellow fever 17D-204 vaccine: a 12-year retrospective analysis of large-scale production. Vaccine. 2007;25(15):2941-2950.
53. Wamala JF, et al. Epidemiological and laboratory characterization of a yellow fever outbreak in northern Uganda, October 2010-January 2011. Int J Infect Dis. 2012;16(7):e536-e542.
54. Edupuganti S, et al. A randomized, double-blind, controlled trial of the 17D yellow fever virus vaccine given in combination with immune globulin or placebo: comparative viremia and immunogenicity. Am J Trop Med Hyg. 2013;88(1):172-177.
55. Costin JM, et al. Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop. J Virol. 2013;87(1):52-66.